Randomized trials of artemisinin-piperaquine, dihydroartemisinin-piperaquine phosphate and artemether-lumefantrine for the treatment of multi-drug resistant falciparum malaria in Cambodia-Thailand border area
© Song et al; licensee BioMed Central Ltd. 2011
Received: 12 April 2011
Accepted: 10 August 2011
Published: 10 August 2011
Drug resistance of falciparum malaria is a global problem. Sulphadoxine/pyrimethamine-resistant and mefloquine-resistant strains of falciparum malaria have spread in Southeast Asia at lightning speed in 1980s-1990s, and the Cambodia-Thailand border is one of the malaria epidemic areas with the most severe forms of multi-drug resistant falciparum malaria.
Artemisinin-piperaquine (AP), dihydroartemisinin-piperaquine phosphate (DHP) and artemether-lumefantrine (AL) were used to treat 110, 55 and 55 uncomplicated malaria patients, respectively. The total dosage for adults is 1,750 mg (four tablets, twice over 24 hours) of AP, 2,880 mg (eight tablets, four times over two days) of DHP, and 3,360 mg (24 tablets, six times over three days) of AL. The 28-day cure rate, parasite clearance time, fever clearance time, and drug tolerance of patients to the three drugs were compared. All of the above methods were consistent with the current national guidelines.
The mean parasite clearance time was similar in all three groups (66.7 ± 21.9 hrs, 65.6 ± 27.3 hrs, 65.3 ± 22.5 hrs in AP, DHP and AL groups, respectively), and there was no remarkable difference between them; the fever clearance time was also similar (31.6 ± 17.7 hrs, 34.6 ± 21.8 hrs and 36.9 ± 15.4 hrs, respectively). After following up for 28-days, the cure rate was 95.1%(97/102), 98.2%(54/55) and 82.4%(42/51); and the recrudescence cases was 4.9%(5/102), 1.8%(1/55) and 17.6%(9/51), respectively. Therefore, the statistical data showed that 28-day cure rate in AP and DHP groups was superior to AL group obviously.
The patients had good tolerance to all the three drugs, and some side effects (anoxia, nausea, vomiting, headache and dizziness) could be found in every group and they were self-limited; patients in control groups also had good tolerance to DHP and AL, there was no remarkable difference in the three groups.
AP, DHP and AL all remained efficacious treatments for the treatment of falciparum malaria in Cambodia-Thailand border area. However, in this particular setting, the AP regimen turned out to be favourable in terms of efficacy and effectiveness, simplicity of administration, cost and compliance.
The trial was registered at Chinese Clinical Trial Register under identifier 2005L01041.
Malaria kills around one million people each year, although is a preventable and treatable infectious disease . Because malaria is a disease that affects mostly poor and vulnerable population, it perpetuates a vicious cycle of poverty in the developing world. Malaria can be prevented, diagnosed and treated with a combination of available tools. However, it has been estimated that USD 4.2 billion is needed each year to fully fund the fight against malaria .
Drug resistant falciparum malaria is a global problem. Sulphadoxine/pyrimethamine and mefloquine resistant strains of falciparum parasites have spread quickly throughout Southeast Asia in 1980s-1990s, and the Cambodia-Thailand border is one of the endemic regions with the most severe multi-drug resistant falciparum malaria [3–6]. WHO has recommended the use of artemisinin combination therapy (ACT) to improve anti-malarial effectiveness and to keep the selection of drug-resistant parasites to a minimum . Now more than 60 countries have switched to ACT for treating malaria, however, the wide-spread application of ACT has been limited by high cost [8, 9].
Dihydroartemisinin-piperaquine phosphate in a fixed-dose preparation of dihydroartemisinin 40 mg and piperaquine phosphate 320 mg has been shown to be highly effective in treating falciparum malaria with an efficacy of over 90% in China, Vietnam, and Cambodia [10–12]. Artemether-lumefantrine (20 mg of artemether and 120 mg of lumefantrine) is another ACT that is administered in six consecutive doses: four tablets each at 0 hours and 8 hours on the first day, then twice daily on the two consecutive days. Lumefantrine is a highly lipophilic substance, and the oral bioavailability varies considerably among individuals, and increases greatly if the drug is administered after a meal rich in fat . This remains a limitation to the effective usage of the drug because uptake may be reduced in fasting patients.
Artemisinin-piperaquine was recently developed by Chinese scientists and has shown good efficacy and safety in a two-day treatment course . Piperaquine is a 4-chloroquinoline (1,3-bis[1-(7-chloro-4'-quinolyl)-4'-piperazinyl]) and was used to replace chloroquine in China in 1970s-1980s. It has been shown that patients' tolerance to piperaquine was better than to piperaquine phosphate. Additionally, piperaquine can reduce the treatment time and cost [9, 15].
The pharmacodynamics studies of artemisinin and its derivatives have shown that artemisinin (ART) and its derivatives are characterized by a quick absorption, wide distribution and quick excretion in vivo. Clinical trials of ART in the treatment of uncomplicated falciparum malaria, conducted in 2002 (Li Guoqiao and others, unpublished data) showed that ART could quickly inhibit the growth of parasite at the dosage of 2 mg/kg with no significant difference in the parasite clearance time betweem ART and dihydroartemisinin (DHA) at the same dosage. DHA is the active metabolite of artemether and artesunate, which are widely used, and ART derivative must be given for 7 days for optimum cure rate if administered alone. Therefore, combining an ART derivative with another anti-malarial drug with a long half-life will shorten treatment time and is considered the treatment of choice for falciparum malaria [8, 17].
In this trial, the effectiveness and safety of the three drugs for the treatment of uncomplicated falciparum malaria were compared and evaluated for developing an optimal anti-malarial regimen.
Study site and recruitment procedures
The trial was conducted in Pursat Referral Hospital, Pursat province, Cambodia. Pursat is located in the western part of the country bordering Thailand. It is located between the Tonle Sap lake and the northern end of the Cardamom Mountains. The patients for this trial came from the forest area in the Cambodia and Thailand boarder, where multi-drug resistant falciparum malaria is widespread.
The implementation of this study is according to the "Agreement of Cambodia-China Fast Malaria Control Co-operation" and "National Ethics Committee for Health Research (No.03G/03NECHR)" signed by Guangzhou University of Chinese Medicine, China, and the Ministry of Health, Kingdom of Cambodia.
It was a prospective, open labeled, randomized controlled trial conducted on patients with microscopically confirmed symptomatic of falciparum malaria, between seven and 65 years of age. All patients with symptoms of malaria, such as fever, and who had not been administrated any anti-malarial drug, including sulphonamide, tetracycline or trimethoprim, in the previous week, were enrolled . A standard data sheet was used to record demographic information, details of symptoms and their duration, and anti-malarial history. Clinical examination, vital signs and axillary temperature were documented. Giemsa-stained thick and thin blood films were used to confirm parasite species and parasitaemia.
Inclusion criteria: (1) patients with clinical symptoms of malaria, such as fever (axillary temperature≥37.5°C), (2) age ranged from seven to 65 years, (3) peripheral blood smears showed that falciparum malaria asexual parasite were 1,000~100,000/μl, (4) no anti-malarial had been taken within seven days prior to the onset of symptoms or admission, including sulphonamide, tetracycline or trimethoprim.
Exclusion criteria: (1) pregnant women;(2) lactating mothers; (3) children under seven years of age, senior persons elder than 65 years of age; (4) patients with severe vomiting or diarrhoea, or other signs of severe malaria; (5) febrile diseases other than falciparum malaria; (6) exiting before the 28-day follow up and/or lack of follow-up data; (7) patients identified as re-infection by PCR were also excluded from the final cure rate and recrudescence rate calculation.
Randomization and masking
Patients were allocated to three treatment arms based on a pre-generated randomization list made in blocks of 20 that was produced and held independently of the field teams by a statistician. The individual allocations were kept in sealed, opaque envelopes and opened only after enrolment by the field team. Patients and clinical field workers were not blinded to the treatment arm after allocation. Microscopists were blinded to treatment allocation at follow-up examinations. Adverse events were assessed by symptom enquiry at every visit.
Drugs and regimen
AP tablets containing 62.5 mg artemisinin (ART) and 375 mg piperaquine (PQ) per tablet were provided by Artepharm Co., Ltd., China (batch No. was 20030820). DHP tablets containing 40 mg dihydroartemisinin (DHA) and 375 mg piperaquine phosphate (PQP) were provided by Guangzhou Holleykin Pharmaceutical Co., Ltd. (batch No. was 20030301). AL tablets containing 20 mg artemether and 120 mg lumefantrine were obtained from Beijng Novartis Pharm Ltd. (batch No. was 20030822). The regimens of AP, DHP and AL were listed in Additional file 1, Table S1.
At enrollment, a full physical examination, including a neurological examination and a medical history, was performed. Thick and thin blood smears were examined by microscopy, and routine haematology was performed. Drug administration was observed by study physicians. If vomiting occurred within 1 h of dosing, the medications were re-administrated. The patients were kept in the hospital for 7 days or until parasites were cleared and were followed-up weekly till D28 from the start of treatment or whenever he/she felt sick within 28 days. At each follow-up, blood smear was done via a finger prick. Blood spots were collected from those with reappearance of asexual parasitaemia. All information was recorded on a standard case record form.
A total of 245 cases of uncomplicated malaria were enrolled for this study. The patients were separated into three random groups with 122 cases in AP group, 61 cases in DHP group and 62 cases in AL groups. And complete data from 110, 55 and 55 patients, respectively, were obtained and analyzed.
Laboratory tests and outcome measurement
Patients were observed in the hospital for 7 days and followed up at D14, D21 and D28 for any symptoms or malaria parasites changes. Temperature was taken every six hours and once daily after it returned to normal(37.5°C) for 24 hours. Ward rounds were done twice daily in the morning and afternoon, and side effects were inquired and recorded according to the "Side Effects Record Form".
Thick and thin blood smears were taken at 7 AM and 5 PM from D0 to D4 to calculate the number of asexual form per 200 WBCs (White Blood Cells). If the number of parasites < 1/200 WBC, 200 fields were examined to identify parasite clearance. Three consecutive negative blood smears (from D5 to D7) indicated clearance of parasite. For follow-ups, blood smears were taken at D14, D21 and D28 to investigate recrudescence. If a patient had fever, he or she was advised to go back to the hospital for further examination. Blood spots collected D0 and positive blood smears during 28-day follow up were kept for qualitative PCR analysis. Blood spots of patients whose blood smears were positive within 28-day follow up were sent to the Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam, for PCR qualitative analysis to differentiate re-infection and recrudescence.
WBC and RBC (Red Blood Cell) counts and electrocardiogram examination were done at D0 and D7. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), direct bilirubin (DBIL), creatinine (CR) and blood urea nitrogen(BUN)were also examined at D0 and D7. Abnormal items found at D7 were re-examined every week until the patient recovered.
The following four main efficacy parameters were used: Early Treatment Failure (ETF); Late Clinical Failure (LCF); Late Parasitological Failure (LPF); Adequate Clinical and Parasitological Response (ACPR) . The occurrence rate of side effects (any symptoms and objective sign having appeared or aggravated after the administration) was recorded. Functions of liver and kidney and electrocardiogram before and after drug administration were checked in order to evaluate the toxicity and side effects of drug to the major organs.
Polymerase chain reaction (PCR)
The patients in the trial continued to live in the area of transmission, therefore, re-infection during the four weeks of follow-up was possible. Then, PCR-genotyping were used to distinguish recrudescence from re-infection. Blood samples were taken at baseline (D0) and on the day of reappearance of parasitaemia . The nested PCR of three polymorphic marker genes [Merozoite Surface Antigen-1 (MSA-1), Merozoite Surface Antigen-1 (MSA-2), and Glutamine-rich Protein (GLURP)] were conducted in University of Oxford Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam. PCR products were analyzed by agarose gel electrophoresis. Patients with the same parasite PCR profiles in the first and second infections were considered to have a recrudescent infection.
Statistic analysis was conducted using SAS 6.12. Data were presented as means ± standard deviation (SD) or as the geometric mean and range. All statistical tests were two-tailed, and a significance level of 0.05 was used.
The study was approved by the National Ethics Committee for Health Research of the Ministry of Health, Phnom Penh, Kingdom of Cambodia, and the Ethics Committee of Guangzhou University of Chinese Medicine, Guangzhou, China. This ethics approval of the trial describes recruitment of patients with uncomplicated infection with P. falciparum, with treatments for AP, DHP and AL, then research on the therapeutic efficacy and safety. The clinical trials registry number was 2005L01041.
Patient recruitment and participant flow
Patient age, symptoms, and other clinical measurements
Number of patients
(n = 110)
(n = 55)
(n = 55)
Mean age, years(range)
mean duration of fever (in days) (range)
Body temperature (°C), mean (range)
Hepatomegly rate (%)
Splenomegly rate (%)
Efficacy and parasite clearance time of the three treatment groups
(n = 110)
(n = 55)
(n = 55)
Lost of follow-up (%)
Early Treatment Failure(%)
Late Clinical Failure(%, 95%CI)
ACPR (%, 95% CI)
109 (99.1, 97.31~100.86%)
ACPR by Intention-to-treat analysis on D28 (%)
ACPR adjusted by PCR on D28
Parasite clearance time, mean ± SD hours
66.7 ± 21.9*Δ
65.6 ± 27.3Δ
65.3 ± 22.5
Fever clearance time, mean ± SD hours
31.6 ± 17.7*Δ
34.6 ± 21.8
36.9 ± 15.4
The 28-day cure rates adjusted after PCR analysis were 97/102 (95.1%), 54/55(98.2%), 42/51 (82.4%) for AP, DHP and AL, respectively (Table 2). There was no significant difference between AP and DHP (P > 0.05). The 28-day cure rate in the AP group was significantly higher than that in the AL group (P < 0.05) (Table 2). The parasite and fever clearance time in the three groups were similar (P > 0.05) (Table 2).
There were no serious adverse events recorded during the trial. All of the three study drugs appeared to be well tolerated.
Haematology, electrocardiogram and biochemistry
No abnormal changes in haemotology and electrocardiogram were observed in the three study groups. Slightly increases in AST, ALT, BIL, BUN and CR measurements were found at D0 in all three groups, and most of them returned to normal ranges at D7. At D7, there were two cases with high TBIL in the AP group, one case with high AST and two cases with high CR, but they became normal at D14. There were four cases with high CR in the DHP group at D7; again they became normal at D14. There were two cases with high TBIL, three cases with high AST and one case with high BUN in the AL group at D7, and they returned normal at D14.
No obvious side effects related to the drugs were found in all the three groups. Although symptoms of anoxia, nausea, vomiting, headache and dizziness were observed in some patients, which was similar to those observed in Chinese healthy volunteers and in Vietnamese patients, as well as in Rwandan children [10, 22–26]. The occurrence rate of side effects was low. Comparing the results of haematology, biochemistry and electrocardiogram between those before and after drug administration showed no obvious toxic reactions related to drugs. The patients in the three groups had good tolerance to the drugs. Although more side effects caused by piperaquine phosphate in DHP than that by piperaquine base in AP combination were reported previously [27, 28], the data presented here did not show any differences in the two groups. In 1998, WHO launched Roll Back Malaria campaign, which aimed to reduce the global number of deaths due to malaria in half by 2010 . However, until 2004, the global number of people having died of malaria had not declined, because the high prices of ACT have delayed timely drug distribution [16, 18]. In East Africa, failure rates of chloroquine and sulphadoxine-pyrimethamine treatment were 64% and 45%, respectively, and children deaths due to malaria increased by 11-fold [8, 29]. Therefore, it is imminent to develop affordable ACT, that is cheaper for people in malaria-endemic countries.
The 28-day cure rate of AP for uncomplicated falciparum malaria was high, the patients had good tolerance to AP as shown above, and by taking four tablets as the total dosage for adults over a 24-hour treatment was convenient and help to improve patients' compliance. Hence, this dosage was recommended for the expanding clinical trial (Phase III).
In this study, three different forms of ACTs (AP, DHP and AL) were compared in the multi-drug resistant falciparum malaria epidemic areas in the Cambodia-Thailand border.
The data from this report demonstrated that the AP regimen turned out to be favourable in terms of efficacy and effectiveness, simplicity of administration, cost and compliance in this particular setting, and it might play an important role for malaria control in the near future.
Acknowledgements and Funding
We thank Xinzhuan Su for assistance in manuscript preparation. The implement of the study is according to the "Agreement of Cambodia-China Fast Malaria Control Co-operation" signed by Guangzhou University of Chinese Medicine and the Ministry of Health, kingdom of Cambodia. The study was supported by Science and Technology Planning Project of the Ministry of Science and Technology of the People's Republic of China (No. 2006DFA33300), and Science and Technology Planning Project of Guangdong province of the People's Republic of China (2005A30101009).
- World Health Organization, 2010: World malaria report. Geneva: World malaria report, (WHO/HTM/GMP/2010.12)
- Roll Back Malaria Partnership: What is malaria?. [http://www.rollbackmalaria.org/malariaMessages.html]
- D'Alessandro U, Buttiens H: History and importance of antimalarial drug resistance. Trop Med Int Health. 2001, 6: 845-848. 10.1046/j.1365-3156.2001.00819.x.View ArticlePubMedGoogle Scholar
- Nosten F, Ter Kuile F, Chongsuphajaisiddhi T, Luxemburger C, Webster HK, Edstein M, Phaipun L, Thew KL, White NJ: Mefloquine-resistant falciparum malaria on the Thai-Burmese border. Lancet. 1991, 337: 1140-1143. 10.1016/0140-6736(91)92798-7.View ArticlePubMedGoogle Scholar
- Ter Kuile FO, Nosten F, Thieren M, Luxemburger C, Edstein MD, Chongsuphajaisiddhi T, Phaipun L, Webster HK, White NJ: High-dose mefloquine in the treatment of mutidrugs-resistance falciparum malaria. J Infect Dis. 1992, 166: 1393-1400. 10.1093/infdis/166.6.1393.View ArticlePubMedGoogle Scholar
- National Center for Parasitology, Entomology and Malaria Control, Ministry of Health: Annual National Conference of National Center for Parasitology Entomology and Malaria Control. 2003, Phnom Penh, CambodiaGoogle Scholar
- Roll Back malaria Technical Consultation: Antimalarial drug combination therapy. Geneva: World Health Organization, WHO/CDS/RBM/2001.35
- World Health Organization: Guidelines for the treatment of malaria. 2006, Geneva: WHO, 21-22.Google Scholar
- Davis TM, Hung TY, Sim IK, Karunajeewa HA, Ilett KF: Piperaquine: a resurgent antimalarial drug. Drugs. 2005, 65: 75-87. 10.2165/00003495-200565010-00004.View ArticlePubMedGoogle Scholar
- Nguyen XT, Trieu NT, Nguyen CP, Nguyen XT, Bui D, G Dennis S, Marina C, Michael DE: Open label randomized comparison of dihydroartemisinin-piperaquine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in central Vietnam. Trop Med Int Health. 2009, 14: 504-511. 10.1111/j.1365-3156.2009.02269.x.View ArticleGoogle Scholar
- Song JP, Duong S, Suou S, Thou T, Ses S, Sim Y, Tan B, Li GQ: Clinical research of dihydroartemisinin-piperaquine with uncomplicated falciparum malaria. Natl Med J China. 2003, 83: 1099-1100.Google Scholar
- Mey BD, Timothy MED, Sean H, Sandra I, Khim N, Thierry F, Yi P, Chiv L, Doung S: Efficacy and safety of dihydroartemisinin-piperaquine (DHP) in Cambodian children and adults with uncomplicated falciparum malaria. Clin Infect Dis. 2002, 35: 1469-1476. 10.1086/344647.View ArticleGoogle Scholar
- Ezzet F, Van VM, Nosten F, Looareesuwan S, White NJ: Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother. 2000, 44: 697-704. 10.1128/AAC.44.3.697-704.2000.PubMed CentralView ArticlePubMedGoogle Scholar
- Trung TN, Tan B, Van Phuc D, Song JP: A randomized, controlled trial of artemisinin-piperaquine vs dihydroartemisinin-piperaquine phosphate in treatment of falciparum malaria. Chin J Integr Med. 2009, 15: 189-192. 10.1007/s11655-009-0189-6.View ArticlePubMedGoogle Scholar
- Krudsood S, Tangpukdee N, Thanchatwet V, Wilairatana P, Srivilairit S, Pothipak N, Jianping S, Guoqiao L, Brittenham GM, Looareesuwan S: Dose ranging studies of new artemisinin-piperaquine fixed combinations compared to standard regimens of artemisisnin combination therapies for acute uncomplicated falciparum malaria. Southeast Asian J Trop Med Public Health. 2007, 38: 971-978.PubMed CentralPubMedGoogle Scholar
- Woodrow CJ, Haynes RK, Krishna S: Artemisinins. Postgrad Med J. 2005, 81: 71-78. 10.1136/pgmj.2004.028399. ReviewPubMed CentralView ArticlePubMedGoogle Scholar
- World Health Organization: Guidelines for the treatment of malaria -- 2nd edition. 2010, Geneva: WHO, 19-21.Google Scholar
- World Health Organization: Assessment and monitoring of antimalarial drug efficacy for the treatment of uncompcicated falciparum malaria. 2003, Geneva: WHOGoogle Scholar
- Denis MB, Tsuyuoka R, Lim P, Lindegardh N, Yi P, Top SN, Socheat D, Fandeur T, Annerberg A, Christophel EM, Ringwald P: Efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia. Trop Med Int Health. 2006, 11: 1800-1807. 10.1111/j.1365-3156.2006.01739.x.View ArticlePubMedGoogle Scholar
- Djimdé A, Lefèvre G: Understanding the pharmacokinetics of Coartem. Malar J. 2009, Suppl 1: S4-ReviewView ArticleGoogle Scholar
- White NJ, van Vugt M, Ezzet F: Clinical pharmacokinetics andpharmacodynamics and pharmacodynamics of artemetherlumefantrine. Clin Pharmacokinet. 1999, 37: 105-125. 10.2165/00003088-199937020-00002.View ArticlePubMedGoogle Scholar
- Tan B, Song JP, He YQ, Guo WZ, Guo XB, Li GQ: Tolerance of oral artemisinin piperaquine tablets in Chinese healthy volunteers. Chin J Clin Pharmacol. 2009, 25: 405-407.Google Scholar
- Karema C, Fanello CI, van Overmeir C, van Geertruyden JP, van Doren W, Ngamije D, D'Alessandro U: Safety and efficacy of dihydroartemisinin/piperaquine (DHP) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwandan children. Trans R Soc Trop Med Hyg. 2006, 100: 1105-1011. 10.1016/j.trstmh.2006.01.001.View ArticlePubMedGoogle Scholar
- Tangpukdee N, Krudsood S, Thanachartwet W, Chalermrut K, Pengruksa C, Srivilairit S, Silachamroon U, Wilairatana P, Phongtananant S, Kano S, Looareesuwan S: An open randomized clinical trial of Artekin(DHP) vs artesunate-mefloquine in the treatment of acute uncomplicated falciparum malaria. Southeast Asian J Trop Med Public Health. 2005, 36: 1085-1091.PubMedGoogle Scholar
- Denis MB, Davis TM, Hewitt S, Incardona S, Nimol K, Fandeur T, Poravuth Y, Lim C, Socheat D: Efficacy and safety of dihydroartemisinin-piperaquine (DHP) in Cambodian children and adults with uncomplicated falciparum malaria. Clin Infect Dis. 2002, 35: 1469-1476. 10.1086/344647.View ArticlePubMedGoogle Scholar
- Jinrong W, Xinggang W, Zijian L, Yan L: Malaria prevention survey for administration dihydroartemisinin piperaquine by officers and soldiers stationed in Sudan. Prac J Med & Pharm. 2009, 26: 36-37.Google Scholar
- Hung TY, Davis TM, Ilett KF, Karunajeewa H, Hewitt S, Denis MB, Lim C, Socheat D: Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br J Clin Pharmacol. 2004, 57: 253-262.PubMed CentralView ArticlePubMedGoogle Scholar
- Jinbo G, Zijian F, Huazhong L, Canjun Zh, Jun G, Gang Zhu, Fanghong Y, Dongshan Zhu: Analysis of side effects caused by piperaquine phosphate for malaria prophylaxis in population. China Trop Med. 2008, 8: 541-543.Google Scholar
- Brockman A, Paul RE, Anderson TJ, Hackford I, Phaiphun L, Looareesuwan S, Nosten F, Day KP: Application of genetic markers to the identification of recrudescent Plasmodium falciparum infections on the northwestern border of Thailand. Am J Trop Med Hyg. 1999, 60: 14-21.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.